跳至主要内容
临床试验/JPRN-jRCT1030230229
JPRN-jRCT1030230229招募中未知

Invasive cerebral small vessel function assessment study for HTRA1-related cerebral small vessel disease including CARASI

Onodera Osamu0 个研究点目标入组 25 人开始时间: 2023年7月14日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Other

入排标准

年龄范围
>= 20age old 至 < 80age old(—)

入选标准

  • The patient group is defined as those between 20 and 80 years of age with confirmed HTRA1 mutation or with clinical symptoms and imaging findings consistent with HTRA1-associated cerebral small vessel disease in second-degree relatives of HTRA1 mutation-positive patients.
  • The healthy group is those who are between 20 and 80 years of age and have not been clinically diagnosed with dementia.

排除标准

  • 1) Patients who have been treated with a prohibited concomitant drug within the last 12 weeks prior to enrollment.
  • 2) Patients who have initiated or changed the dosage of a prohibited concomitant medication within the past 4 weeks prior to enrollment.
  • 3) Patients with active infections requiring systemic treatment
  • 4) Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2)
  • 5) Patients with severe hepatic impairment (AST (GOT) or ALT (GPT) > 100 U/L)
  • 6) Patients with abnormal serum sodium or potassium levels requiring therapeutic correction.
  • 7) Patients with a 12-lead ECG showing QT prolongation or shortening requiring therapeutic correction.
  • 8) Patients with a history of cerebral infarction, intracranial hemorrhage, transient ischemic attack, or cerebral aneurysm with a high probability of rupture diagnosed within the last 12 weeks prior to enrollment.
  • 9) Patients being treated for or with a history of coronary artery disease (angina, myocardial infarction).
  • 10) Patients with poorly controlled respiratory disease (asthma, chronic obstructive pulmonary disease, etc.)
  • 11) Patients with occlusion or significant stenosis of the main intracranial artery or carotid artery
  • 12) Patients with systolic blood pressure below 100 mmHg
  • 13) Patients with pulse rate less than 45 beats/minute or greater than 120 beats/minute
  • 14) Patients with drug abuse or alcoholism
  • 15) Patients unable to obtain an adequate head MR scan
  • 16) Patients with active malignant neoplastic disease
  • 17) Patients who are pregnant, lactating, or who may become pregnant between the date of informed consent and the date of study completion.
  • 18) Patients who have participated in other studies involving the administration of investigational products within 24 weeks prior to enrollment.
  • 19) Other patients deemed ineligible for the study by the investigator or others.

研究者

发起方
Onodera Osamu

相似试验